Medical/Pharmaceuticals
Neurophet Participates ASNR 2025: Showcasing Clinical Utility of 'Neurophet AQUA AD'
* Co-CEO Jake Junkil Been joins Industry Collaboration Session to present Neurophet's brain imaging analysis technologies, including Neurophet AQUA AD * Company accelerates partnerships with global pharmaceutical companies and neurology KOLs to drive collaboration in Alzheimer's disease clinic...
2025-05-21 21:00
2614
BioDlink Clinches Brazil GMP Audit to Strengthen Emerging Markets Growth
* International recognition of quality system with GMP-compliance in the key markets ofBrazil, Indonesia, Egypt, Colombia and Argentina * Passed its first-ever on-site PIC/S audit, reinforcing its strong commitment to stringent international regulatory standards * Demonstrated BioDlink's cap...
2025-05-21 20:30
2066
SK bioscience Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine
* No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 toRussia * Company plans to export PCV13 vaccine components * "We aim for the global PCV market with our 21-valent and next-generation pneumococcal vaccines currently...
2025-05-21 20:00
2233
China's Aphranel MagiCCrystal CaHA Filler Debuts Globally, Ushering in a New Era of Regenerative Aesthetic Medicine
SHANGHAI, May 21, 2025 /PRNewswire/ -- On May 8, 2025, Shanghai Moyom Biotechnology Co., Ltd. unveiled its breakthrough regenerative aesthetic innovation, Aphranel MagiCCrystal CaHA Filler, during an international product debut at The Grand Halls inShanghai, a historic building on the Bund. ...
2025-05-21 20:00
2013
Accropeutics Announces Positive Data from Phase 2 Trial of AC-201, an oral, selective TYK2/JAK1 Inhibitor, for the treatment of Moderate-to-Severe Plaque Psoriasis
* Phase 2 primary endpoint of PASI-75 and key secondary endpoints met in all of the three dosing groups at Week 12 * AC-201 was generally well tolerated at all dose levels with no SAEs or AEs leading to discontinuation * Efficacy and safety findings from this Phase 2 trial support advancing ...
2025-05-21 08:50
1629
Registrational Phase III AMPLIFY trial in biochemical recurrence of prostate cancer commences
SYDNEY, May 20, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that it has commenced ...
2025-05-20 21:02
2041
Minghui Pharmaceutical Announces First Patient Dosed in the Phase Ⅱ Combination Study of PD-1xVEGF Bispecific and TROP-2 ADC in Advanced NSCLC
SHANGHAI, May 20, 2025 /PRNewswire/ -- Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative therapies in immunology and oncology, today announced that the first patient has been successfully dosed in a Phase Ⅱ clinical trial evaluating the safety a...
2025-05-20 18:18
3242
BioFlag Showcases Innovative Probiotic Solutions at Vitafoods Europe 2025
BARCELONA, Spain, May 20, 2025 /PRNewswire/ -- BIOFLAG CO.,LTD.(Bioflag), a
leading probiotic enterprise located inChina, proudly unveiled its
scientifically validated functional probiotic solutions at Vitafoods Europe
2025, drawing high attention from global media.
2025-05-20 18:00
1396
WuXi XDC Received Multiple Awards from 2025 Extel (previously "Institutional Investor") Ranking in Diverse Categories
SHANGHAI, May 19, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate market, today announced that the company received multiple top awards- "Best CEO", "Bes...
2025-05-20 09:44
2988
United Imaging Emphasizes Differentiated Technology at ISMRM 2025
Among the highlights were a completely unique whole-body 8 ch-parallel transmit coil on the 5T uMR® Jupiter, and an FDA pending- 3T MRI that provides visualization of the body in motion. HOUSTON, May 19, 2025 /PRNewswire/ -- United Imaging, a global manufacturer of modern medical imaging technol...
2025-05-20 00:00
2008
Lunit Surpasses 1 Million Mammograms in U.S. One Year After Volpara Acquisition
Building on Volpara's breast health expertise, Lunit strengthens its U.S. presence—now delivering AI-powered breast cancer screening across 200 imaging sites SEOUL, South Korea, May 19, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, ...
2025-05-19 21:00
2356
Porton Advanced Announces Collaboration with Hualong Biological to Accelerate MATC Cell Therapy Development for Solid Tumor Treatment Breakthroughs
SUZHOU, China, May 19, 2025 /PRNewswire/ -- Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Hualong Biological, an innovator in novel cancer therapeutics....
2025-05-19 21:00
2029
Datasea Secures $100 Million in 5G+AI Contracts from Major Clients, Reinforcing Strategic Expansion and Long-Term Growth
The renewal from a key client demonstrates strong loyalty, while a new major deal reflects continued growth momentum heading into FY2026. BEIJING, May 19, 2025 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada-based technology company specializing in acoustic high...
2025-05-19 20:30
1921
2025 EASL Congress Spotlight: CG-0416 Preclinical Data Unveils A Groundbreaking Dual-Action Therapy Targeting Obesity and MASH
——A First-in-Class Hydrolysis-Activated Liver-Targeted THR-β Prodrug Demonstrating A Dual Advantage of Fat Reduction and Muscle Preservation SHANGHAI, May 16, 2025 /PRNewswire/ -- At the European Association for the Study of the Liver (EASL) Annual Congress, CureGene Pharmaceuticals("CureGene") ...
2025-05-17 08:41
3852
SNS812, an innovative siRNA drug from Oneness and Microbio (Shanghai), selected for ATS 2025 oral presentation, demonstrating world-leading clinical outcomes in COVID-19 treatment
TAIPEI, May 16, 2025 /PRNewswire/ -- The broad-spectrum antiviral siRNA drug SNS812, co-developed by Oneness Biotech (4743.TW) and Microbio (Shanghai), has been selected for oral presentation at the prestigious 2025 American Thoracic Society (ATS) International Conference. The presentation will d...
2025-05-16 23:10
4336
Visionary: Pioneering a New Era in Cancer Screening
TORONTO, May 16, 2025 /PRNewswire/ -- Recently, Visionary has achieved a significant breakthrough in the field of early cancer screening and home self - testing technologies, attracting widespread attention from the industry. American Precision Biotech Inc. is a subsidiary of Visionary Holdings. ...
2025-05-16 21:30
2605
Xuanzhu Biopharm's Xuanyuening® (BireociclibTablets) Approved for Dual Indications, Bringing Innovative Breakthroughs to Breast Cancer Treatment
HONG KONG, May 15, 2025 /PRNewswire/ -- On May 15, 2025, the latest announcement released by the National Medical Products Administration attracted widespread attention in the oncology community and the pharmaceutical market. Bireociclib tablets (trade name: Xuanyuening®), a Class 1 anti-tumor ne...
2025-05-16 11:57
2043
Datasea Reports Third Fiscal Quarter 2025 Revenue of $10.4 Million Up 653.6% Year-over-Year
DTSS' AI-Powered Technology Serves as a Unifying Core Innovation for its 5G Multimodal Digital Platform and Acoustic High-Tech Segment BEIJING, May 15, 2025 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada-based technology company specializing in 5G+AI multimodal ...
2025-05-15 21:30
4029
Dizal to Present Promising Clinical Data on Golidocitinib and DZD8586 for the Treatment of Lymphoma at the Coming International Hematology Conferences
* The latest 2-year follow-up data on golidocitinib as a maintenance therapy for peripheral T-cell lymphoma (PTCL) patients who achieved tumor response after first-line systemic therapy will be presented orally at the 2025 ICML * A pooled safety and efficacy analysis of two Phase I/II studies ...
2025-05-15 18:09
2319
Tsingke Showcases at AACR 2025 -- Advancing Global Cancer Research with Integrated Synthesis Solutions
BEIJING, May 15, 2025 /PRNewswire/ -- Tsingke Biotech proudly participated in theAACR Annual Meeting 2025, held this April in Chicago, USA. As one of the world's premier events in oncology research, AACR gathered global leaders from academia and industry to explore the future of cancer diagnostic...
2025-05-15 14:12
1866
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
Colebrook Bosson Saunders Chooses India for First Executive Dialogue Exploring Future of Workspaces and Technology
[Picked up by 296 media titles]
2025-12-16 14:26
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
Synvo AI and Sobat Bisnis Group (SBG) Forge Strategic Partnership to Bring Secure, Context-Aware Enterprise AI to Indonesia and Southeast Asia
[Picked up by 288 media titles]
2025-12-16 08:00
Tiiny AI Reveals World's Smallest Personal AI Supercomputer, Verified by Guinness World Records
[Picked up by 285 media titles]
2025-12-10 16:00
